12
Treatment/Management of TAK
Figure 2. Overview of Treatment of TAK Based on Clinical
and Radiographic Assessments
Active TAK not on
immunosuppressive therapy
Consider switching
to another non-GC
immunosuppressive
agent (MTX, AZA,
TNFi, or TCZ)
Taper daily oral GC;
Continue non-GC
immunosuppressive
agent
High-dose daily oral GC + non-GC
immunosuppressive agent: MTX, AZA, +/-TNFi
Treatment option,
Conditional recommendation
Treatment option,
Strong recommendation
Disease status decision point
Assessed disease status
NO YES
AZA, azathioprine; CT, computed tomography; FDG-PET, 18F-flourodeoxyglucose positron
emission tomography; GC, glucocorticoids; MR, magnetic resonance; MTX, methotrexate;
TAK, Takayasu arteritis; TCZ, tocilizumab; TNFi, tumor necrosis factor inhibitor
Clinical
remission
